Anti-cancer tgfb2 agents with immunotherapeutics
AssigneeGmp Biotechnology Limited
InventorVuong TRIEU
Life of this patent
Estimating the term…
Abstract
This invention relates to methods for treating or ameliorating the symptoms of cancer in a human or animal subject with pharmaceutical compositions designed to promote anti-tumor effects. Exemplary synergistic pharmaceutical therapies include compositions having a combination of active agents including agents for inhibiting or suppressing expression of TGF-β2, immune checkpoint inhibitor agents, and interleukin immunotherapeutic active agents. One or more biomarkers can be used to select subjects who benefit from the method.
Claims25
A method for treating or ameliorating the symptoms of cancer in a subject in need, the method comprising:
- administering a composition comprising an agent for inhibiting or suppressing expression of TGF-β2;
- administering an immune checkpoint inhibitor;
- and
- administering an interleukin immunotherapeutic agent to the subject.
An agent for inhibiting or suppressing expression of TGF-β2 in combination with an immune checkpoint inhibitor and an interleukin immunotherapeutic active agent for use in treating or ameliorating the symptoms of cancer.
A composition comprising an agent for inhibiting or suppressing expression of TGF-β2 and a pharmaceutically acceptable carrier for use in the preparation of a medicament or for treating or ameliorating the symptoms of a cancer in a subject in combination with an immune checkpoint inhibitor and an interleukin immunotherapeutic active agent.
Dependencies are inferred from the claim text.